Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Current Assets (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Current Assets for 13 consecutive years, with $11162.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 49.96% year-over-year to $11162.0, compared with a TTM value of $11162.0 through Nov 2025, down 49.96%, and an annual FY2025 reading of $18437.0, down 41.25% over the prior year.
  • Current Assets was $11162.0 for Q4 2025 at CNBX Pharmaceuticals, down from $18437.0 in the prior quarter.
  • Across five years, Current Assets topped out at $2.1 million in Q2 2021 and bottomed at $11162.0 in Q4 2025.
  • Average Current Assets over 5 years is $417419.7, with a median of $157426.5 recorded in 2023.
  • The sharpest move saw Current Assets soared 173.56% in 2021, then plummeted 89.67% in 2022.
  • Year by year, Current Assets stood at $964586.0 in 2021, then tumbled by 89.67% to $99685.0 in 2022, then soared by 51.41% to $150936.0 in 2023, then tumbled by 85.22% to $22308.0 in 2024, then tumbled by 49.96% to $11162.0 in 2025.
  • Business Quant data shows Current Assets for CNBX at $11162.0 in Q4 2025, $18437.0 in Q3 2025, and $18615.0 in Q2 2025.